All News

New products and services available to urologists.

images

images

images

David A. Bloom, MD, has been appointed chairman of the department of urology at the University of Michigan Medical School in Ann Arbor. Dr. Bloom, a pediatric urologic surgeon who is the Jack Lapides Professor of Urology, replaces James E. Montie, MD, who relinquished the chairmanship to continue his research on the quality of care for patients with urologic cancer.

Cosmos Trading, Inc., is conducting a voluntary nationwide recall of its dietary supplement product sold under the name Rhino Max (Rhino V Max) after lab analysis found that the product contains aminotadalafil, an analogue of tadalafil, making Rhino Max (Rhino V Max) an unapproved drug.

The American Association for Cancer Research (AACR) has announced the formation of the AACR-FDA-NCI Cancer Biomarkers Collaborative to facilitate the use of validated biomarkers in clinical trials and, ultimately, their use in evidence-based oncology and cancer medicine. The collaborative includes researchers from academia, government, and industry, as well as patient advocacy groups.

A new imaging technique, known as a functional diffusion map, can measure the effectiveness of treatment for prostate cancer metastatic to bone. The technique involves measuring diffusion of water within tumors.

The androgen receptor appears to play a key role in the development of bladder cancer, revealing why the disease is more prevalent in men than in women, according to a study published in the Journal of the National Cancer Institute (2007; 99:558-68). This finding could open the door to new types of treatment.

Urologists and other physicians are facing another battle over Medicare fees, with a 9.9% cut looming for 2008 and further reductions that will be imposed on physicians who provide in-office imaging services as a result of the Deficit Reduction Act of 2005.

A predictive model that incorporates the androgen receptor concentration of prostate cancer cells can identify patients who have an increased risk of clinical failure 5 years after radical prostatectomy.

Recent research suggests that the common fusion of two genes may point to a molecular basis for prostate cancer.

Epidemiologic studies show that prostate cancer does not occur at the same rate all over the world.

Researchers at Johns Hopkins have made significant progress on the development of a new serum biomarker known as Early Prostate Cancer Antigen-2.

Products and services from manufacturers who are exhibiting at the American Urological Association meeting in Anaheim.

Those in town for AUA 2007 will be delighted to learn that Anaheim, heavily vested in tourism, offers a vast collection of culinary options to satisfy even the most discriminating appetite.

Once known as the strawberry-growing capital of the United States, the area is cultivating a new field as a vacation destination, with something for every age and every interest, from scuba and baseball, to shopping and wine tours, to amusement parks, theater, and concerts, all within Anaheim proper or a short drive from the city.

The treatment of metastatic renal cell carcinoma has undergone significant changes.

Androgen deprivation therapy's documented adverse effects on cardiac risk factors might translate into an increased risk of cardiac mortality for older prostate cancer patients.

A predictive model that incorporates the androgen receptor concentration of prostate cancer cells can identify patients who have an increased risk of clinical failure 5 years after radical prostatectomy.

New research findings have provided further evidence that 5-alpha-reductase inhibitors may play a role in preventing prostate cancer.

The dilemma surrounding the value of widespread PSA screening for early detection of prostate cancer remains unresolved.

A virus that is known to cause leukemia in mice, xenotropic murine leukemia-related virus (XMRV), also may be responsible for prostate cancer in humans.

A single PSA value measured in men between 44 and 50 years of age is highly predictive of the development of clinically diagnosed prostate cancer up to 25 years later.

Updated life expectancy tables, text on surveillance, treatment failure, and ADT validate diverse therapeutic approaches to prostate cancer.

A new biomarker, which is under investigation at Johns Hopkins, shows great potential to address both of these controversial issues.

As a practicing urologist and former journal editor, Jerry G. Blaivas, MD, has confronted many ethical issues facing urologists today.

Many patients, practices, and hospitals are having a difficult time finding a urologist this year, and that difficulty is going to grow as the next 2 decades tick past.